Study on the Incidence of Malignant Neoplasms in Patients with Parkinson's Disease and Heterozygous Mutation of the GBA Gene

What this Trial Is About

This research investigates the occurrence of malignant tumors in people with Parkinson's disease (PD) who carry a specific gene change called a heterozygous pathogenic variant in the GBA1 gene. The study compares these individuals with those who have idiopathic PD (PD without these gene changes) and with the general population. The study aims to understand if there is a higher risk of cancer in PD patients with the GBA1 mutation and to explore patterns by sex, age, and tumor type. The study collects data from about 3000 PD patients across multiple movement disorder centers in Italy, including around 500 with the GBA1 mutation and 2500 with idiopathic PD. Information about cancer cases for these patients is gathered from local cancer registries. Participants are grouped into those with PD and the GBA1 mutation and those with idiopathic PD, with diagnoses based on established criteria. Participants' medical histories related to cancer are reviewed using cancer registry data. The main outcome is to compare the rate of malignant tumors in PD patients with GBA1 mutations to the general population over a period from birth up to 36 months after joining the study. Secondary analyses include comparisons between the different PD groups and detailed descriptions of cancer types by patient characteristics. The study helps understand cancer risks in PD and may guide future patient care.

Study on the Incidence of Malignant Neoplasms in Patients with Parkinson's Disease and Heterozygous Mutation of the GBA Gene